Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 930

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Open access
Peters, S., Adjei, A.A., Gridelli, C., Reck, M., Kerr, K., Felip, E.·2012·Annals of Oncology
DOI 10.1093/annonc/mds226
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mds226

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 41

  1. Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 · DOI · Paper page
  2. Malvezzi, 2012, European cancer mortality predictions for the year 2012, Ann Oncol, 23, 1044, 10.1093/annonc/mds024 · DOI · Paper page
  3. Wakelee, 2007, Lung cancer incidence in never smokers, J Clin Oncol, 25, 472, 10.1200/JCO.2006.07.2983 · DOI · Paper page
  4. Edwards, 2005, Annual report to the nation on the status of cancer 1975–2002, featuring population-based trends in cancer treatment, J Natl Cancer Inst, 97, 1407, 10.1093/jnci/dji289 · DOI · Paper page
  5. Toh, 2006, Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity, J Clin Oncol, 24, 2245, 10.1200/JCO.2005.04.8033 · DOI · Paper page
  6. Travis, 2011, International Association for the Study of Lung Cancer/American Thoracic Society. European Respiratory Society international multidisciplinary classification of lung adenocarcinoma, J Thorac Oncol, 6, 244, 10.1097/JTO.0b013e318206a221 · DOI · Paper page
  7. Rekhtman, 2012, Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations, Clin Cancer Res, 18, 1167, 10.1158/1078-0432.CCR-11-2109 · DOI · Paper page
  8. Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448 · DOI · Paper page
  9. Shaw, 2009, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK, J Clin Oncol, 27, 4247, 10.1200/JCO.2009.22.6993 · DOI · Paper page
  10. Yi, 2012, Detection of Anaplastic Lymphoma Kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review, Mol Diagn Ther, 16, 143, 10.1007/BF03262202 · doi:10.1007/bf03262202
  11. Schiller, 2002, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N Engl J Med, 346, 92, 10.1056/NEJMoa011954 · DOI · Paper page
  12. Ardizzoni, 2007, Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis, J Natl Cancer Inst, 99, 847, 10.1093/jnci/djk196 · DOI · Paper page
  13. Ciuleanu, 2009, Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study, Lancet, 374, 1432, 10.1016/S0140-6736(09)61497-5 · DOI · Paper page
  14. Reck, 2009, Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil, J Clin Oncol, 27, 1227, 10.1200/JCO.2007.14.5466 · DOI · Paper page
  15. Pirker, 2009, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial, Lancet, 373, 1525, 10.1016/S0140-6736(09)60569-9 · DOI · Paper page
  16. Pirker, 2012, EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study, Lancet Oncol, 13, 33, 10.1016/S1470-2045(11)70318-7 · DOI · Paper page
  17. Pujol, 2006, Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials, Lung Cancer, 51, 335, 10.1016/j.lungcan.2005.11.001 · DOI
  18. Park, 2007, Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer, J Clin Oncol, 25, 5233, 10.1200/JCO.2007.10.8134 · DOI · Paper page
  19. Gridelli, 2004, Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel, Ann Oncol, 15, 419, 10.1093/annonc/mdh087 · DOI · Paper page
  20. 1999, The elderly lung cancer vinorelbine Italian Study Group, J Natl Cancer Inst, 91, 66
  21. Lilenbaum, 2009, Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials, J Thorac Oncol, 4, 869, 10.1097/JTO.0b013e3181a9a020 · DOI
  22. Quoix, 2011, Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial, Lancet, 378, 1079, 10.1016/S0140-6736(11)60780-0 · DOI · Paper page
  23. Gridelli, 2003, Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial, J Natl Cancer Inst, 95, 362, 10.1093/jnci/95.5.362 · DOI · Paper page
  24. Shaw, 2011, Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis, Lancet Oncol, 12, 1004, 10.1016/S1470-2045(11)70232-7 · DOI · Paper page
  25. Robinet, 2001, Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1, Ann Oncol, 12, 59, 10.1023/A:1008338312647 · DOI · Paper page
  26. Porta, 2011, Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation, Eur Respir J, 37, 624, 10.1183/09031936.00195609 · DOI · Paper page
  27. Paz-Ares, 2012, J Clin Oncol, 30, 10.1200/JCO.2011.39.7646 · DOI · Paper page
  28. Di Maio, 2009, Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer, J Clin Oncol, 27, 1836, 10.1200/JCO.2008.17.5844 · DOI · Paper page
  29. Hanna, 2004, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J Clin Oncol, 22, 1589, 10.1200/JCO.2004.08.163 · DOI · Paper page
  30. Shepherd, 2000, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J Clin Oncol, 18, 2095, 10.1200/JCO.2000.18.10.2095 · DOI · Paper page
  31. Kim, 2008, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial, Lancet, 372, 1809, 10.1016/S0140-6736(08)61758-4 · DOI · Paper page
  32. Vamvakas, 2010, Pemetrexed (MTA) compared with erlotinib (ERL) in pretreated patients with advanced non-small cell lung cancer (NSCLC): Results of a randomized phase III Hellenic Oncology Research Group trial, J Clin Oncol, 28, 10.1200/jco.2010.28.15_suppl.7519 · DOI
  33. Lynch, 1996, Optimal therapy of malignant pleural effusions, Int J Oncol, 8
  34. Rosen, 2004, Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial, Cancer, 100, 2613, 10.1002/cncr.20308 · DOI · Paper page
  35. Henry, 2011, Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma, J Clin Oncol, 29, 1125, 10.1200/JCO.2010.31.3304 · DOI · Paper page
  36. Tanvetyanon, 2008, Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis, J Clin Oncol, 26, 1142, 10.1200/JCO.2007.14.2091 · DOI · Paper page
  37. Gaspar, 2010, The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline, J Neurooncol, 96, 17, 10.1007/s11060-009-0060-9 · DOI · Paper page
  38. Aoyama, 2006, Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial, JAMA, 295, 2483, 10.1001/jama.295.21.2483 · DOI · Paper page
  39. Andrews, 2004, Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial, Lancet, 363, 1665, 10.1016/S0140-6736(04)16250-8 · DOI · Paper page
  40. Mordant, 2012, Which metastasis management allows long-term survival of synchronous solitary M1b non-small cell lung cancer?, Eur J Cardiothorac Surg, 41, 617, 10.1093/ejcts/ezr042 · DOI
  41. Pfannschmidt, 2010, Surgical treatment of oligometastatic non-small cell lung cancer, Lung Cancer, 69, 251, 10.1016/j.lungcan.2010.05.003 · DOI

Cited by

See all 930

Metadata

Authors
Peters, S., Adjei, A. A., Gridelli, C., Reck, M., Kerr, K., & Felip, E.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2012-10
Volume
23
Pages
vii56-vii64
ISSN
0923-7534 (ISSN-L)
DOI
10.1093/annonc/mds226
OpenAlex
W2144330816
Cited by
930
References
25
FWCI
75.89
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. https://app.cochat.ai/papers/10.1093/annonc/mds226
The paper
Peters, S., Adjei, A. A., Gridelli, C., Reck, M., Kerr, K., & Felip, E. (2012). Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. https://doi.org/10.1093/annonc/mds226

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.